HRP20170593T1 - Inhibitori csf-1r za liječenje tumora na mozgu - Google Patents
Inhibitori csf-1r za liječenje tumora na mozgu Download PDFInfo
- Publication number
- HRP20170593T1 HRP20170593T1 HRP20170593TT HRP20170593T HRP20170593T1 HR P20170593 T1 HRP20170593 T1 HR P20170593T1 HR P20170593T T HRP20170593T T HR P20170593TT HR P20170593 T HRP20170593 T HR P20170593T HR P20170593 T1 HRP20170593 T1 HR P20170593T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- use according
- glioma
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title claims 4
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 8
- 206010018338 Glioma Diseases 0.000 claims 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- -1 ukraine Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (8)
1. Spoj, naznačen time, da ima sljedeću formulu (I):
u kojoj R1 je
gdje R’ je Me ili Et; i
R2 je
ili njegova farmaceutski prihvatljiva sol, pri čemu se on upotrebljava u liječenju tumora na mozgu kod pojedinog sisavca.
2. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, naznačen time, da se radi o sljedećem spoju formule (I):
3. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, naznačen time, da se radi o sljedećem spoju formule (I):
4. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da tumor na mozgu je gliom.
5. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 4, naznačen time, da gliom je multiformni glioblastom.
6. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da tumor mozga je metastaza na mozgu, astrocitom (uključujući glioblastom), oligodendrogliom, ependimom, ili miješani gliom.
7. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da se spoj formulira za uporabu zajedno s koterapeutskim sredstvom.
8. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 7, naznačen time, da je koterapeutsko sredstvo odabrano od antiangiogenskih sredstava, bevacizumaba sa ili bez irinotekana, nitrozourea kao što je karmustin (BCNU), platinskih spojeva kao što je cis-platinum (cisplatin), alkilacijskog sredstva kao što je temozolomid, inhibitora kinaze tirozina (gefitinib ili erlotinib), ukraina, i kanabinoida.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482723P | 2011-05-05 | 2011-05-05 | |
| US201261624861P | 2012-04-16 | 2012-04-16 | |
| EP12720761.1A EP2704713B1 (en) | 2011-05-05 | 2012-05-04 | Csf-1r inhibitors for treatment of brain tumors |
| PCT/US2012/036589 WO2012151523A1 (en) | 2011-05-05 | 2012-05-04 | Csf-1r inhibitors for treatment of brain tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170593T1 true HRP20170593T1 (hr) | 2017-07-14 |
Family
ID=46062775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170593TT HRP20170593T1 (hr) | 2011-05-05 | 2017-04-12 | Inhibitori csf-1r za liječenje tumora na mozgu |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20140065141A1 (hr) |
| EP (1) | EP2704713B1 (hr) |
| JP (1) | JP6046702B2 (hr) |
| KR (1) | KR101938431B1 (hr) |
| CN (1) | CN103501785B (hr) |
| BR (1) | BR112013028095B1 (hr) |
| CA (1) | CA2834696C (hr) |
| CY (1) | CY1119642T1 (hr) |
| DK (1) | DK2704713T3 (hr) |
| EA (1) | EA023999B1 (hr) |
| ES (1) | ES2622527T3 (hr) |
| HR (1) | HRP20170593T1 (hr) |
| HU (1) | HUE032754T2 (hr) |
| LT (1) | LT2704713T (hr) |
| MX (1) | MX347616B (hr) |
| PL (1) | PL2704713T3 (hr) |
| PT (1) | PT2704713T (hr) |
| SI (1) | SI2704713T1 (hr) |
| WO (1) | WO2012151523A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014147631A1 (en) * | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
| US10722517B2 (en) | 2015-05-08 | 2020-07-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of glioma |
| US10316097B2 (en) * | 2015-05-27 | 2019-06-11 | Ucb Biopharma Sprl | Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody |
| CN108367070B (zh) * | 2015-11-04 | 2022-10-28 | 杜克大学 | 免疫毒素与检查点抑制剂的组合治疗 |
| WO2018069892A1 (en) * | 2016-10-14 | 2018-04-19 | Novartis Ag | Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide |
| US10537563B2 (en) | 2016-10-14 | 2020-01-21 | Novartis Ag | Methods for treating ocular disease using inhibitors of CSF-1R |
| WO2018093591A1 (en) | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
| AU2018275894A1 (en) | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| AU2018275891A1 (en) | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
| JP2020526194A (ja) | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
| MA50057A (fr) | 2017-09-01 | 2020-07-08 | Juno Therapeutics Inc | Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2020036987A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| AU2019387497A1 (en) | 2018-11-30 | 2021-06-24 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| KR20210110811A (ko) | 2018-11-30 | 2021-09-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법 |
| CN110468210A (zh) * | 2019-09-12 | 2019-11-19 | 暨南大学 | Cdc45作为胶质母细胞瘤标志物及其作为治疗靶点的应用 |
| CN115398231A (zh) | 2019-12-06 | 2022-11-25 | 朱诺治疗学股份有限公司 | 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法 |
| BR112023004719A2 (pt) * | 2020-09-21 | 2023-04-18 | Hutchison Medipharma Ltd | Compostos heteroaromáticos e usos dos mesmos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100721656B1 (ko) | 2005-11-01 | 2007-05-23 | 주식회사 엘지화학 | 유기 전기 소자 |
| PL2010496T3 (pl) * | 2006-04-14 | 2011-01-31 | Astrazeneca Ab | 4-Anilinochinolino-3-karboksyamidy jako inhibitory kinazy CSF-1R |
| CN101432281B (zh) * | 2006-04-19 | 2013-08-28 | 诺瓦提斯公司 | 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
| LT2010528T (lt) * | 2006-04-19 | 2017-12-27 | Novartis Ag | 6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai |
| UA93085C2 (en) | 2006-04-20 | 2011-01-10 | Янссен Фармацевтика Н.В. | Inhibitors of c-fms kinase |
| AU2008254425A1 (en) * | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
-
2012
- 2012-05-04 ES ES12720761.1T patent/ES2622527T3/es active Active
- 2012-05-04 LT LTEP12720761.1T patent/LT2704713T/lt unknown
- 2012-05-04 SI SI201230916A patent/SI2704713T1/sl unknown
- 2012-05-04 EA EA201391629A patent/EA023999B1/ru not_active IP Right Cessation
- 2012-05-04 CN CN201280021878.2A patent/CN103501785B/zh active Active
- 2012-05-04 PT PT127207611T patent/PT2704713T/pt unknown
- 2012-05-04 DK DK12720761.1T patent/DK2704713T3/en active
- 2012-05-04 WO PCT/US2012/036589 patent/WO2012151523A1/en active Application Filing
- 2012-05-04 PL PL12720761T patent/PL2704713T3/pl unknown
- 2012-05-04 CA CA2834696A patent/CA2834696C/en active Active
- 2012-05-04 BR BR112013028095-6A patent/BR112013028095B1/pt not_active IP Right Cessation
- 2012-05-04 EP EP12720761.1A patent/EP2704713B1/en active Active
- 2012-05-04 HU HUE12720761A patent/HUE032754T2/en unknown
- 2012-05-04 US US14/114,878 patent/US20140065141A1/en not_active Abandoned
- 2012-05-04 JP JP2014509491A patent/JP6046702B2/ja active Active
- 2012-05-04 KR KR1020137031960A patent/KR101938431B1/ko active IP Right Grant
- 2012-05-04 MX MX2013012939A patent/MX347616B/es active IP Right Grant
-
2015
- 2015-06-29 US US14/754,152 patent/US20150306085A1/en not_active Abandoned
-
2017
- 2017-04-10 CY CY20171100426T patent/CY1119642T1/el unknown
- 2017-04-12 HR HRP20170593TT patent/HRP20170593T1/hr unknown
-
2018
- 2018-06-04 US US15/996,945 patent/US10537561B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012250574A8 (en) | 2016-07-28 |
| AU2012250574A1 (en) | 2013-11-28 |
| EA023999B1 (ru) | 2016-08-31 |
| AU2012250574B2 (en) | 2016-07-07 |
| EP2704713A1 (en) | 2014-03-12 |
| CA2834696A1 (en) | 2012-11-08 |
| WO2012151523A1 (en) | 2012-11-08 |
| US20140065141A1 (en) | 2014-03-06 |
| CN103501785A (zh) | 2014-01-08 |
| HUE032754T2 (en) | 2017-10-30 |
| EP2704713B1 (en) | 2017-01-18 |
| LT2704713T (lt) | 2017-04-25 |
| DK2704713T3 (en) | 2017-04-24 |
| US20150306085A1 (en) | 2015-10-29 |
| CA2834696C (en) | 2019-07-23 |
| PL2704713T3 (pl) | 2017-08-31 |
| KR20140029475A (ko) | 2014-03-10 |
| SI2704713T1 (sl) | 2017-05-31 |
| US10537561B2 (en) | 2020-01-21 |
| MX2013012939A (es) | 2014-02-27 |
| ES2622527T3 (es) | 2017-07-06 |
| US20190030013A1 (en) | 2019-01-31 |
| BR112013028095A2 (pt) | 2016-12-27 |
| BR112013028095B1 (pt) | 2020-03-03 |
| JP2014513136A (ja) | 2014-05-29 |
| JP6046702B2 (ja) | 2016-12-21 |
| CN103501785B (zh) | 2016-10-26 |
| EA201391629A1 (ru) | 2016-01-29 |
| KR101938431B1 (ko) | 2019-01-14 |
| PT2704713T (pt) | 2017-04-24 |
| CY1119642T1 (el) | 2018-04-04 |
| MX347616B (es) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170593T1 (hr) | Inhibitori csf-1r za liječenje tumora na mozgu | |
| PH12016501204A1 (en) | Syk inhibitors | |
| NI201500167A (es) | Compuestos químicos | |
| NZ715747A (en) | Syk inhibitors | |
| NI201100048A (es) | Aminotriazolopiridinas y su uso como inhibidores de la cinasa. | |
| EA201000947A1 (ru) | Производные тиазола, применимые в качестве ингибиторов киназы pi3 | |
| NI201500134A (es) | Derivados de 2-((4-amino-3-(3-flúor-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il) metil)-3-(2-(trifluorometil)bencil)quinazolina-4(3h)-ona y su uso como inhibidores de fosfoinositida 3-quinasas | |
| PE20151860A1 (es) | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd | |
| UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
| JP2014513136A5 (hr) | ||
| TR201904327T4 (tr) | Dimetilbenzoik asit bileşikleri. | |
| AR065531A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas. | |
| MA38884A1 (fr) | Composé de triazolopyridine, compositions et procédés d'utilisation associés | |
| PE20151754A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
| EA201200087A1 (ru) | 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k | |
| EA200901504A1 (ru) | Производные пиразолона, как ингибиторы pde4 | |
| MX2016004203A (es) | Inhibidores de pi3k y mtor conformacionalmente restringidos. | |
| RU2010145439A (ru) | Средство для лечения поражений печени, вызванных воздействием химических или биологических агентов | |
| TH150497A (th) | สารรวมของตัวยับยั้งฟอสฟาทิดิลอิโนซิทอล-3-ไคเนส (PI3K) และ ตัวยับยั้ง mTOR | |
| TH135295A (th) | อนุพันธ์ไพราโซโลสไปโรคีโทนสำหรับใช้เป็นสารยับยั้งอะซีทิล-CoA คาร์บอกซิเลส | |
| BR112017006798A2 (pt) | composto, composição farmacêutica, inibidor de tnap, métodos para o tratamento ou a profilaxia de uma doença ou condição e para a inibição de tnap, e, uso de um composto. | |
| TH128143B (th) | ตัวยับยั้ง jak2 และการใช้ของมันสำหรับการบำบัดโรคมัยอีโลโพรลิเฟอเรทิฟและมะเร็ง | |
| TH96556A (th) | อิมิดาโซลีนที่ถูกแทนที่สี่ตำแหน่งที่ 4,4,5,5 | |
| TH145797A (th) | สารประกอบที่ออกฤทธิ์ทางเภสัชกรรมเป็นสารยับยั้ง axl | |
| TH183191A (th) | อนุพันธ์พิริโดนซึ่งมีหมู่เททระไฮโดรไพแรนิลเมธิล |